Michael Walters was 25 years old and barely a year into his first job after university when he was diagnosed with non-Hodgkin lymphoma. Chemotherapy didn’t work. Neither did radiotherapy or immunotherapy.
Then his doctors told him about another possibility: a treatment that would remove some of his own immune cells, genetically reprogram them to recognize his cancer, and put them back into his body to attack it. There was another problem.
A hospital in Melbourne quoted Walters as much as $600,000 for the treatment. So instead of traveling to Australia, the New Zealander got on a plane to Shanghai. He paid less than half as much.
In August 2026, Walters learned that his cancer was in complete remission.
His story is part of a surprising shift now taking place in cancer care. Patients from wealthy countries are traveling to China for CAR-T cell therapy, drawn by dramatically lower reported prices, expanding treatment options, and a Chinese biotech industry that has moved remarkably quickly in a field pioneered largely in the United States.
According to reporting from The Wall Street Journal, CAR-T treatment can cost roughly $150,000 to $230,000 in China, compared with $550,000 to $850,000 in the United States, although those figures don’t necessarily include the same services and shouldn’t be interpreted as direct out-of-pocket comparisons.
And cost isn’t the only reason patients are looking east.
In June 2026, China approved the world’s first CAR-T therapy for a solid tumor, opening another front in a treatment that until recently had been used primarily against certain blood cancers.
So how did China become a destination for one of the most advanced cancer treatments in the world?
What Is CAR-T Therapy?
CAR-T therapy is a personalized form of immunotherapy that essentially turns a patient’s own immune cells into a targeted cancer treatment.
Doctors collect T cells, a type of white blood cell, from the patient’s blood. Those cells are then genetically engineered to carry receptors that recognize a particular protein on cancer cells. The modified cells are multiplied in a laboratory before being infused back into the patient.
Once inside the body, the engineered cells can recognize and attack cancer cells carrying their designated target.
For some people with certain cancers that have stopped responding to chemotherapy, radiation, or other treatments, CAR-T can offer another option when relatively few remain.
But making a treatment individually for each patient is complicated, time-consuming, and expensive. That is part of what makes developments in China particularly interesting.
China’s Rise as a CAR-T Destination
Dr. Sairah Ahmed, director of the CAR-T program at the University of Texas MD Anderson Cancer Center, described China’s approach to The Wall Street Journal this way:
“China has basically done to CAR-T cell therapy the same thing that it’s done to other industries – they’ve industrialized it.”
Ahmed has advised some of her overseas patients to seek CAR-T treatment there.
Shanghai’s SinoUnited Hospital has reportedly treated roughly three dozen international CAR-T patients from 12 countries since beginning to offer the therapy to international patients in 2023.
Cost is an obvious part of the appeal.
The Wall Street Journal reported treatment costs ranging from about $150,000 to $230,000 in China, compared with $550,000 to $850,000 in the United States.
Those figures need some context.
CAR-T treatment isn’t simply the price of the engineered cells. Patients may require hospitalization, monitoring, medications, intensive care, and treatment for potentially serious complications. What is included in quoted treatment costs can therefore differ substantially between hospitals and countries.
For insured American patients, the amount they personally pay can also be far below the total cost of care, depending on insurance coverage and financial assistance.
International patients considering China face other expenses as well, including flights, accommodation, potentially lengthy stays, and follow-up care after returning home.
Still, when the underlying treatment can cost hundreds of thousands of dollars, the difference is large enough to get people’s attention.
China Has Also Crossed a Major CAR-T Milestone
For some patients, however, traveling to China isn’t only about saving money.
It’s about gaining access to a treatment that may not yet be available at home.
Josh Bronkhorst, another New Zealand patient featured in The Wall Street Journal’s reporting, traveled to Shanghai after conventional treatments for his advanced gastrointestinal cancer failed.
Jiahui International Cancer Center reported treating the first international patient with satri-cel, a CAR-T therapy targeting a protein known as Claudin18.2 that can be expressed by certain gastrointestinal tumors.
In June 2026, China’s National Medical Products Administration approved satricabtagene autoleucel, or satri-cel, developed by CARsgen Therapeutics Holdings.
It became the first CAR-T cell therapy to receive regulatory approval for a solid tumor indication. The approval covers certain patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction cancers who have already undergone multiple previous treatments.
That matters because CAR-T’s greatest successes so far have come against blood cancers.
The six FDA-approved CAR-T products currently available in the United States are used for certain blood cancers, while none has yet received FDA approval for a solid tumor.
Solid tumors have proven considerably more difficult for engineered immune cells to attack because of factors including the complex environment surrounding the tumor and the difficulty of identifying targets that distinguish cancer cells from healthy tissue.
Dr. Carl June, who helped pioneer CAR-T therapy at the University of Pennsylvania, described China’s solid-tumor approval as “great news” and said it could help maintain momentum in the field.
Why CAR-T Manufacturing Speed Matters
China’s emergence in CAR-T hasn’t happened overnight.
Since the first CAR-T therapy was approved by the FDA in 2017, Chinese researchers and biotechnology companies have invested heavily in engineered cell therapies, manufacturing processes, and new treatment targets.
Manufacturing is particularly important because traditional CAR-T isn’t something that can simply be taken off a pharmacy shelf.
Each patient’s cells must be collected, engineered, expanded, tested, and returned for infusion.
Conventional CAR-T manufacturing typically takes around one to two weeks, while newer abbreviated manufacturing approaches may potentially shorten that process to 24 to 72 hours.
For someone with rapidly progressing cancer, turnaround time can matter. A patient must remain healthy enough to undergo the treatment while their engineered cells are being prepared.
China’s growing CAR-T infrastructure, lower reported treatment costs, international hospital services, and expanding range of therapies have therefore created a combination that is attracting patients from abroad.
You can find related coverage of how engineered immune cell therapies are being explored for other conditions in our article on immunotherapy and artery plaque.
CAR-T Therapy Comes With Serious Risks
The potential of CAR-T therapy can make the treatment sound almost futuristic, but it carries significant risks and requires specialized medical care.
One of the most important is cytokine release syndrome (CRS).
When large numbers of engineered immune cells become activated, they can release inflammatory signaling molecules throughout the body. Symptoms can range from fever and fatigue to dangerously low blood pressure, breathing problems, and organ dysfunction.
Clinical reviews have reported CRS in a substantial proportion of CAR-T recipients, although the frequency and severity vary considerably depending on the particular therapy. Severe cases require rapid treatment, often including the drug tocilizumab.
Neurological complications can also occur.
Known as immune effector cell-associated neurotoxicity syndrome (ICANS), these effects can include headache, confusion, difficulty speaking, delirium, seizures, and, in rare severe cases, cerebral edema or coma.
Many cases resolve, but some patients require intensive care.
Infections are another concern because both the underlying cancer treatment and CAR-T therapy can leave patients immunocompromised.
There are longer-term questions as well. In 2023, the FDA began investigating reports of secondary T-cell cancers occurring after treatment with BCMA-directed and CD19-directed CAR-T therapies. Subsequent reviews have examined the reported cases and the potential relationship to treatment. The FDA has recommended lifelong monitoring for secondary malignancies in CAR-T recipients.
For international patients, this makes the medical facility itself especially important. CAR-T treatment requires access to teams capable of recognizing and rapidly treating complications, as well as a plan for follow-up care once the patient returns home.
Patients also need to distinguish between therapies that have received regulatory approval and those still being tested in clinical trials.
Read More: Woman’s Inoperable Brain Tumor Responds Rapidly to New Cancer Treatment
Why Patients Are Looking Beyond Their Own Borders
The patients flying to China aren’t evidence that one country’s cancer system is simply “better” than another. Their stories point to something more interesting: the geography of cutting-edge cancer treatment is changing.
CAR-T therapy was pioneered in the United States, and American cancer centers remain major leaders in the field. But China has rapidly expanded its own CAR-T industry, increased manufacturing capacity, lowered reported treatment costs, and in 2026 became the first country to approve a CAR-T therapy for a solid tumor.
For some patients, particularly those who have exhausted conventional options, those differences can be enough to justify traveling thousands of miles.
There are still major limitations. CAR-T is only appropriate for certain cancers and patients, serious complications can occur, and treatment abroad introduces additional questions about regulation, follow-up care, travel, insurance, and what happens if complications develop after returning home.
And a dramatic remission like Michael Walters’ cannot tell us how another patient will respond.
But his journey from New Zealand to Shanghai illustrates why this trend is attracting attention.
A cancer therapy that can cost hundreds of thousands of dollars and may not even be available for a patient’s particular cancer at home is increasingly being offered elsewhere, sometimes for substantially less.
For CAR-T therapy, China is no longer simply trying to catch up. It is becoming one of the places patients are willing to cross the world to reach.
Disclaimer: This article is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Anyone considering CAR-T therapy or treatment abroad should discuss their options, eligibility, risks, and follow-up care with their oncology team.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: How UnitedHealthcare Came to Represent Everything Wrong With U.S. Health Insurance